14 employees
Navidea develops precision immunodiagnostic agents and immunotherapeutics for patients with cancer, autoimmune, and infectious diseases.
1983
$60M
from 2 investors over 2 rounds
Navidea Biopharmaceuticals raised $60M on May 11, 2015
Investors: CRG LP
Navidea Biopharmaceuticals raised $30M on March 6, 2014
Investors: Oxford Finance LLC